Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Breast Neoplasms 17Neoplasms 9Head and Neck Neoplasms 8Prostatic Neoplasms 7Ovarian Neoplasms 6Lung Neoplasms 5Pancreatic Neoplasms 4Endometrial Neoplasms 4Urinary Bladder Neoplasms 3Rectal Neoplasms 3Oropharyngeal Neoplasms 3Motor Activity 3Kidney Neoplasms 3Health Behavior 3Depression 3Carcinoma, Squamous Cell 3Brain Neoplasms 3Uterine Cervical Neoplasms 2Smoking Cessation 2Multiple Myeloma 2Glioma 2Glioblastoma 2Gastrointestinal Neoplasms 2Fallopian Tube Neoplasms 2Communication 2Colorectal Neoplasms, Hereditary Nonpolyposis 2Carcinoma, Renal Cell 2Anxiety Disorders 2Alopecia 2Xerostomia 1

Interventions

haloperidol decanoate 1fludarabine phosphate 1fludarabine 1Temozolomide 1Surveys and Questionnaires 1Simvastatin 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Lorazepam 1Dexamethasone 1Cyclophosphamide 1Bendamustine Hydrochloride 1AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Neurotoxicity Syndromes × Surveys and Questionnaires × Clear all
NCT01949662 2026-02-13

Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
93 enrolled 14 charts
Other hematologic neoplasm

Delirium, Hematologic Neoplasms, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡